BOSTON--Telik said on Tuesday that its experimental cancer drug failed to improve survival in patients with advanced lung cancer or in patients
with ovarian cancer.
The company said a late-stage, or Phase III, trial of the drug, Telcyta, did not significantly improve survival in patients with advanced lung cancer who had failed other treatments, when compared with patients taking the drug gefitinib. Improving survival was the main goal of the trial.
The company also said a Phase III trial of patients with resistant ovarian cancer also failed to demonstrate significant improvement in survival when compared to patients in the control groups. Improved survival was the main goal of this trial also.